Related Experiment Videos
Strontium ranelate (Fujisawa/Servier)
Isabelle Jupsin1, Julien Collette, Yves Henrotin
1Bone and Cartilage Metabolism Research Unit. CHU Centre-Ville, Policliniques L Brull, Quai Godefroid Kurth 45, 4020 Liège, Belgium.
Current Opinion in Investigational Drugs (London, England : 2000)
|May 19, 2005
Summary
Strontium ranelate (PROTELOS) is a novel osteoporosis treatment. Ongoing phase II trials in Japan are evaluating its efficacy.
Area of Science:
- Pharmacology
- Bone Metabolism
- Drug Development
Background:
- Osteoporosis is a significant global health concern.
- Effective therapeutic agents are needed to manage bone density loss.
- Strontium ranelate represents a new class of osteoporosis medication.
Purpose of the Study:
- To introduce strontium ranelate (PROTELOS) as a treatment for osteoporosis.
- To report on the development and ongoing clinical trials of strontium ranelate.
Main Methods:
- Strontium ranelate, a divalent strontium salt, has been developed.
- Phase II clinical trials were initiated in Japan.
Main Results:
- Strontium ranelate has been launched by Servier for osteoporosis treatment.
- Fujisawa Pharmaceutical is involved in the Japanese development.
Conclusions:
- Strontium ranelate is a promising therapeutic option for osteoporosis.
- Further clinical evaluation is ongoing in Japan.